, Volume 67, Issue 2, pp 175–194

Guidelines and Recommendations for the Management of Anaemia in Patients with Lymphoid Malignancies

Therapy In Practice


Patients with lymphoid malignancies frequently require repetitive and intensive anticancer treatments to induce and maintain disease remission. Anaemia (haemoglobin [Hb] <12 g/dL) is a common and debilitating problem associated with both the malignancy itself and its treatment burden. Anaemia negatively impacts on all aspects of patient quality of life (QOL) and treatment outcomes and survival, particularly in this disease setting.

Widely acknowledged goals of anaemia treatment include Hb correction to ≈12 g/dL, reduction in transfusion requirements and optimisation of patient QOL. Since the introduction of recombinant human erythropoietic therapy, transfusion (once the only anaemia treatment option available) is now primarily reserved for non-responders or those with severe or life-threatening anaemia. Data from randomised, double-blind, placebo-controlled studies, and large, non-randomised, open-label, community-based studies, along with almost 15 years of practical experience, support the assertion that epoetin alfa administered at a dosage of 150–300 U/kg three times weekly or 40 000–60 000U once weekly, both of which are US FDA-approved dose administration schedules, can effectively and safely achieve anaemia treatment goals for the majority of patients with lymphoid malignancies. Data and practical experience collected over the last 5 years on another erythropoietic agent with a slightly longer half-life but lower binding affinity, darbepoetin alfa, show that this agent when administered according to the FDA-approved dose administration schedules (2.25–4.5 µg/kg once weekly or 500µg once every 3 weeks) or according to a commonly-administered dose in clinical practice (3.0–5.0 µg/kg once every 2 weeks) can also effectively and safely correct anaemia, reduce transfusion requirements and improve QOL in many patients with lymphoid malignancies. One comparative head-to-head trial suggested that epoetin alfa might be superior to darbepoetin alfa in anaemic cancer patients receiving chemotherapy with respect to timing and magnitude of Hb correction, although further study is necessary, especially concerning optimal dose administration. Alternative dose administration schedules, such as epoetin alfa 80 000U every 2 weeks from initiation or 80 000U every 3 weeks following initiation with once weekly administration and darbepoetin alfa 4.5 µg/kg every 3 weeks following initiation with once weekly administration, are being actively investigated with the goal of increased flexibility for patients and healthcare providers.

The treatment of anaemia in patients with lymphoid malignancies is an important part of overall disease management, as evidenced by continuous investigation of existing erythropoietic agents and new agents. Although treatment guidelines issued by organisations such as the National Comprehensive Cancer Network (NCCN) and American Society of Hematology (ASH)/American Society of Clinical Oncology (ASCO) suggest intervention with erythropoietic therapy when Hb falls below 10–11 g/dL or based on clinical symptoms, data suggest that anaemia is vastly under-recognised and under-treated. Clearly, an update on the definition, identification and optimal management of anaemia in patients with lymphoid malignancies is warranted.


  1. 1.
    Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 2005; 5: 376–84CrossRefGoogle Scholar
  2. 2.
    Adult non-Hodgkin’s Lymphoma: treatment (updated September 7, 2005) [online]. Available from URL: http://www.nci.nih.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional [Accessed 2006 May 7]
  3. 3.
    Italiano A, Thyss A. Follicular lymphoma: a therapeutic update. Bull Cancer 2005 Oct 1; 92 (10): E57–64PubMedGoogle Scholar
  4. 4.
    Vose JM, Link BK, Grossbard ML, et al. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2005 Nov; 46 (11): 1569–73PubMedCrossRefGoogle Scholar
  5. 5.
    American Cancer Society. Cancer facts and figures 2005 [online]. Available from URL: http://www.cancer.org/docroot/STT/stt_0_2005.asp?sitearea=STT&level=l [Accessed 2007 May 7]
  6. 6.
    Voliotis D, Diehl V. Challenges in treating hematologic malignancies. Sem Oncol 2002 Jun; 29 (3 Suppl. 8): S30–40CrossRefGoogle Scholar
  7. 7.
    Van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ. Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin’s lymphoma. Curr Opin Hematol 2004 Nov; 11 (6): 419–25PubMedCrossRefGoogle Scholar
  8. 8.
    Van Belle SJ, Cocquyt V. Impact of hemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003; 47: 1–11PubMedCrossRefGoogle Scholar
  9. 9.
    Nola M, Pavletic SZ, Weisenburger DD, et al. Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma. Am J Hematol 2004 Sep; 77 (1): 31–5PubMedCrossRefGoogle Scholar
  10. 10.
    Zinzani PL, Tani M, Alinari L. Role of anemia in survival of patients with elderly aggressive non-Hodgkin’s lymphoma after chemotherapy. Leuk Lymphoma 2005 Oct; 46 (10): 1449–54PubMedCrossRefGoogle Scholar
  11. 11.
    National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Published December 12, 2003 [online]. Available from URL: http://ctep.cancer.gov/forms/CTCAEv3.pdf [Accessed 2006 May 7]
  12. 12.
    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999 Oct 6; 91 (19): 1616–34PubMedCrossRefGoogle Scholar
  13. 13.
    Tas F, Eralp Y, Basaran M, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 2002; 25 (4): 371–9PubMedCrossRefGoogle Scholar
  14. 14.
    Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293–306PubMedCrossRefGoogle Scholar
  15. 15.
    Steurer M, Wagner H, Gastl G. Prevalence and management of anaemia in hematologic cancer patients receiving cyclic non-platinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 2004 Jun 30; 116 (11–12): 367–72PubMedCrossRefGoogle Scholar
  16. 16.
    Coiffier B, Guastalla JP, Pujada-Lauraine E, et al. Predicting cancer-associated anaemia in patients receiving nonplatinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001; 37: 1617–23PubMedCrossRefGoogle Scholar
  17. 17.
    Domnikova NP, Degtyareva VV, Nepomnyashchikh LM. Erythropoiesis in patients with aggressive and indolent non-Hodgkin’s lymphomas. Bull Exp Biol Med 2004 Dec; 138 (6): 593–7PubMedCrossRefGoogle Scholar
  18. 18.
    Littlewood T, Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 2002 Jun; 29 (3 Suppl. 8): 40–4PubMedCrossRefGoogle Scholar
  19. 19.
    Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001 Apr; 28 (2 Suppl. 8): 7–14PubMedCrossRefGoogle Scholar
  20. 20.
    La Verde G, Arienti D. Cancer-related fatigue in hematological cancer: hematologist’s and patient’s view. Recenti Prog Med 2002 Sep; 93 (9): 463–9PubMedGoogle Scholar
  21. 21.
    Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 Jul; 34 (3 Suppl. 2): 13–9PubMedGoogle Scholar
  22. 22.
    Birgegard G, Ludwig H, Nortier J, et al. Despite high prevalence of anemia and impact on performance status, anemia treatment rate is low in multiple myeloma/lymphoma patients according to European Cancer Anaemia Survey [abstract]. Blood 2002 Nov 16; 100 (11 Pt 1): 0851Google Scholar
  23. 23.
    Morrow TJ, Volpe S, Gupta S, et al. Anemia of cancer in intermediate-grade non-Hodgkin’s lymphoma. South Med J 2002 Aug; 95 (8): 889–96PubMedGoogle Scholar
  24. 24.
    Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001 Jun 15; 91 (12): 2214–21PubMedCrossRefGoogle Scholar
  25. 25.
    Moullet I, Salles G, Ketterer N, et al. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 1998 Oct; 9 (10): 1109–15PubMedCrossRefGoogle Scholar
  26. 26.
    Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998 Aug; 12 (8): 1281–7PubMedCrossRefGoogle Scholar
  27. 27.
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998 Nov 19; 339 (21): 1506–14Google Scholar
  28. 28.
    Liao Z, Ha CS, Fuller LM, et al. Subdiaphragmatic stage I and II Hodgkin’s disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys 1998 Jul 15; 41 (5): 1047–56PubMedCrossRefGoogle Scholar
  29. 29.
    Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin’s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000 Apr; 18 (7): 1500–7PubMedGoogle Scholar
  30. 30.
    Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002 Oct 1; 100 (7): 2303–20PubMedCrossRefGoogle Scholar
  31. 31.
    Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004 Oct; 40 (15): 2201–16PubMedCrossRefGoogle Scholar
  32. 32.
    National Comprehensive Cancer Network. Practice guidelines in oncology: cancer and treatment-related anemia (v.2.2006). National Comprehensive Cancer Network, Inc., 2006Google Scholar
  33. 33.
    Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002 Aug 15; 95 (4): 888–95PubMedCrossRefGoogle Scholar
  34. 34.
    Gralow JR, Hudis CA, Williams D. Incremental improvements in QOL related to changes in Hb in breast cancer (BC) patients (pts) receiving adjuvant chemotherapy (ADJCT) and QW epoetin alfa therapy [abstract]. Blood 2003 Nov 16; 102 (11): 4392Google Scholar
  35. 35.
    Shasha D, Cremieux P, Harrison L. Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa. J Natl Compr Can Netw 2004; 2 (5): 509–17Google Scholar
  36. 36.
    Demetri GD, Kris M, Wade J, et al., for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998 Oct; 16 (10): 3412–25PubMedGoogle Scholar
  37. 37.
    Fastenau J, Lefebvre P, Duh MS. Evaluation of the relationship between early hemoglobin rise during epoetin alfa treatment and improved patient-reported quality of life. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (post-meeting edition) Jul 15; 22 (14S): 8124Google Scholar
  38. 38.
    McKenzie RS, Lefebvre P, Rosberg J, et al. Comparison of anemia outcomes associated with early response to epoetin alfa (EPO) with QW and TIW dosing. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (post-meeting edition) Jul 15; 22 (14S): 6141Google Scholar
  39. 39.
    Campos SM, Duh MS, Lefebvre P, et al. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw 2005 Nov; 3 (6): 807–16PubMedGoogle Scholar
  40. 40.
    Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003 Jan 11; 361 (9352): 161–9PubMedCrossRefGoogle Scholar
  41. 41.
    Littlewood TJ, Bajetta E, Nortier JW, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001 June 1; 19 (11): 2865–74PubMedGoogle Scholar
  42. 42.
    Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 Suppl. 1: 3–10PubMedCrossRefGoogle Scholar
  43. 43.
    Mulcahy L. The erythropoietin receptor. Semin Oncol 2001; 28 (2 Suppl. 8): 19–23PubMedCrossRefGoogle Scholar
  44. 44.
    McKenzie SR, Heifetz LJ, Duh M-S, et al. Effectiveness of epoetin alfa beyond once-weekly dosing schedules in the oncology community setting [abstract]. Blood 2002 Nov 16; 100: 5591Google Scholar
  45. 45.
    Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003 Nov; 25 (11): 2781–96PubMedCrossRefGoogle Scholar
  46. 46.
    Procrit [prescribing information]. Raritan (NJ): Ortho Biotech Products, Dec 2006Google Scholar
  47. 47.
    Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57: 411–8PubMedCrossRefGoogle Scholar
  48. 48.
    Zagari M, Wacholtz M, Xiu L. An open-label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum-based chemotherapy [abstract]. Proceedings of the 8th European Hematology Association Annual Meeting; 2003 June 13. Lyon, France, 2003: 0177Google Scholar
  49. 49.
    Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001 Jun 1; 19 (11): 2875–82PubMedGoogle Scholar
  50. 50.
    Glaspy J, Bukowski R, Steinberg D, et al., for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997 Mar; 15 (3): 1218–34PubMedGoogle Scholar
  51. 51.
    Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003 Sep 1; 98 (5): 1072–9PubMedCrossRefGoogle Scholar
  52. 52.
    Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2005 Apr 20; 23 (12): 2606–17PubMedCrossRefGoogle Scholar
  53. 53.
    Henry DH. Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update. Expert Opin Pharmacother 2005; 6 (2): 295–310PubMedCrossRefGoogle Scholar
  54. 54.
    Henry DH. Anemia in patients with cancer or undergoing cancer therapy: impact and current treatment practice. Transfusion Alternatives in Transfusion Medicine 2005; 6 (3): 14–25CrossRefGoogle Scholar
  55. 55.
    Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematological malignancies receiving non-platinum chemotherapy. Hematol Oncol 2003; 21: 169–80PubMedCrossRefGoogle Scholar
  56. 56.
    Demetri GD, Glaspy J, Gabrilove J. Hematologic and quality of life benefits of epoetin alfa once weekly vs 3 times weekly in patients with hematologic malignancies [abstract]. Hematol J 2001; 1 (59 Suppl. 1): 193Google Scholar
  57. 57.
    Jones M, Schenkel B, Just J, et al. Epoetin alfa improves quality of life in patients with cancer: results of a meta-analysis. Cancer 2004 Oct 15; 101 (8): 1720–32PubMedCrossRefGoogle Scholar
  58. 58.
    Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin in anemic cancer patients undergoing chemotherapy. Oncologist 2004; 9 (1): 90–6PubMedGoogle Scholar
  59. 59.
    Gregory SA, Xie J. Maintenance dosing with epoetin alfa every two weeks (Q2W) in anemic patients with cancer receiving chemotherapy every one or four weeks: final results [abstract]. Blood 2005 Nov 16; 106 (11): 3770Google Scholar
  60. 60.
    Montoya VP, Xie J. Maintenance dosing with epoetin alfa every three weeks (Q3W) in anemic patients with cancer receiving chemotherapy every three weeks: final results [abstract]. Blood 2005 Nov 16; 106 (11): 3555Google Scholar
  61. 61.
    Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006; Mar 1; 24 (7): 1079–89PubMedCrossRefGoogle Scholar
  62. 62.
    Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U Q2W) vs. weekly dosing (40,000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006 Jul; 22 (7): 1403–13Google Scholar
  63. 63.
    Aranesp [prescribing information]. Thousand Oaks (CA): Amgen Inc., 2006Google Scholar
  64. 64.
    Herrington JD, Davidson SL, Tomita DK, et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005 Jan 1; 62 (1): 54–62PubMedCrossRefGoogle Scholar
  65. 65.
    Glaspy J, Colowick A, Heatherington A, NESP-Oncology Study Group. Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life (t½) in oncology patients [abstract]. Proc Am Soc Clin Oncol 2000; 19: 210Google Scholar
  66. 66.
    Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomized, phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002 Aug 21; 94 (16): 1211–20PubMedCrossRefGoogle Scholar
  67. 67.
    Vadhan-Raj S, Schreiber F, Thomas LC, et al. Every-2-week darbepoetin alfa improves fatigue and energy rating scores in cancer patients undergoing chemotherapy [abstract 2942]. Proc Am Soc Clin Oncol 2003; 22: 732Google Scholar
  68. 68.
    Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003 Jul–Aug; 1 (2): 131–8PubMedGoogle Scholar
  69. 69.
    Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394–403PubMedCrossRefGoogle Scholar
  70. 70.
    Canon J, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006 Feb 15; 98 (4): 273–84PubMedCrossRefGoogle Scholar
  71. 71.
    Blayney DW, Spiridonidis H, Fesen MR, et al. Darbepoetin alfa every 2 weeks to treat chemotherapy-induced anemia: experience in a randomized, open-label study [abstract 3003]. Proc Am Soc Clin Oncol 2003; 22: 747Google Scholar
  72. 72.
    Littlewood TJ, Kallich JD, San Miguel J, et al. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manage 2006; 31: 317–25PubMedCrossRefGoogle Scholar
  73. 73.
    Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004 Feb 15; 100 (4): 859–68PubMedCrossRefGoogle Scholar
  74. 74.
    Boccia RV, Silberstein PT, Tchekmedyian S, et al. Effectiveness of darbepoetin alfa administered every 3 weeks on clinical outcomes in patients with hematologic malignancies and chemotherapy-induced anemia [abstract]. Blood 2005 Nov 16; 206 (11): 3767Google Scholar
  75. 75.
    Taylor K, Ganly P, Charu V. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia [abstract]. Blood 2005 Nov 16; 106 (11): 3556Google Scholar
  76. 76.
    Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microgram every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005 Sep; 10 (8): 642–50PubMedCrossRefGoogle Scholar
  77. 77.
    Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006 May 20; 24 (15): 2290–7PubMedCrossRefGoogle Scholar
  78. 78.
    Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995 Dec 15; 86 (12): 4446–53PubMedGoogle Scholar
  79. 79.
    Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma — a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 1996 Apr 1; 87 (7): 2675–82Google Scholar
  80. 80.
    Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002 May 15; 20 (10): 2486–94PubMedCrossRefGoogle Scholar
  81. 81.
    Boogaerts M, Coiffier B, Kainz C, et al. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003; 88: 988–95PubMedCrossRefGoogle Scholar
  82. 82.
    Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122 (3): 386–93PubMedCrossRefGoogle Scholar
  83. 83.
    Bugelski P, Nesspor T, Spinka-Doms T, et al. Pharmacokinetics and pharmacodynamics of CNTO 528, a novel erythropoietin receptor agonist in normal and anemic rats [abstract]. Blood 2005 Nov 16; 106 (11): 4261Google Scholar
  84. 84.
    Hsieh M, Linde S, Metzger M, et al. Chronic intermittent administration of HIF Prolyl hydroxylase inhibitor significantly induces erythropoietin and increases total hemoglobin in normal rhesus macaques [abstract]. Blood 2005 Nov 16; 106 (11): 570Google Scholar
  85. 85.
    Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005 Nov; 4 (6): 436–40PubMedGoogle Scholar
  86. 86.
    Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent for the treatment of anemia. Exp Hematol 2006 Oct; 34 (10): 1303–11PubMedCrossRefGoogle Scholar
  87. 87.
    Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A Suppl. 2: S2–8PubMedCrossRefGoogle Scholar
  88. 88.
    Eckardt K-U, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865–9PubMedCrossRefGoogle Scholar
  89. 89.
    Casadevall N, Eckardt K-U, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16: S67–9PubMedCrossRefGoogle Scholar
  90. 90.
    Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity, and risks. Nephrol Dial Transplant 2005 May; 20 Suppl. 4: iv9–15PubMedCrossRefGoogle Scholar
  91. 91.
    Rossert J, Pure Red Cell Aplasia Global Scientific Advisory Board (GSAB). Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest 2005 Dec; 35 Suppl. 3: 95–9PubMedCrossRefGoogle Scholar
  92. 92.
    Food and Drug Administration. Department of Health and Human Services/Oncology Drugs Advisory Committee May 4 2004 meeting notes [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/cder04.html [Accessed 2006 May 7]
  93. 93.
    Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006 Jul 19; 3: CD003407Google Scholar
  94. 94.
    Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002; 88: 150–9PubMedGoogle Scholar
  95. 95.
    Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumor growth of human malignancies. Carcinogenesis 2003 Jun; 24 (6): 1021–9PubMedCrossRefGoogle Scholar
  96. 96.
    Glaser CM, Millesi W, Kornek G, et al. Impact of hemoglobin level and use of recombinant human erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50 (3): 705–15PubMedCrossRefGoogle Scholar
  97. 97.
    Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005 Dec 20; 23 (36): 9377–86PubMedCrossRefGoogle Scholar
  98. 98.
    Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005 Oct 1; 23 (28): 6941–8PubMedCrossRefGoogle Scholar
  99. 99.
    Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 Sep 1; 23 (25): 5960–72PubMedCrossRefGoogle Scholar
  100. 100.
    Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 Oct 18; 362 (9392): 1255–60PubMedCrossRefGoogle Scholar
  101. 101.
    Straus DJ, Testa MA, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anemia. Cancer 2006 Oct 15; 107 (8): 1909–17PubMedCrossRefGoogle Scholar
  102. 102.
    Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001 Apr; 28 (2 Suppl. 8): 1–6PubMedCrossRefGoogle Scholar
  103. 103.
    Auerbach M, Ballard H, Trout R, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004 Apr 1; 22 (7): 1301–7PubMedCrossRefGoogle Scholar
  104. 104.
    Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004 May; 113 (9): 1251–3PubMedGoogle Scholar
  105. 105.
    Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy-results of a multicenter, randomized trial [abstract]. Blood 2004 Nov 16; 104 (11): 3696Google Scholar
  106. 106.
    Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005 Aug; 46 (2): 283–9PubMedCrossRefGoogle Scholar
  107. 107.
    Hedenus M, Birgegard GH, Nasman P, et al. Adjuvant intravenous iron therapy potentiates epoetin beta treatment in anemic, non-iron-depleted patients with lymphoproliferative disorders: results of the NIFE study [abstract]. Hematol J 2006 Jun; 91 (1): 0996Google Scholar
  108. 108.
    Henry DH. The role of intravenous iron in cancer-related anemia. Oncology 2006 Jul; 20 (8 Suppl. 6): 21–4PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Joan Karnell Cancer CenterPennsylvania HospitalPhiladelphiaUSA

Personalised recommendations